New connections of medication use and polypharmacy with the gut microbiota composition and functional potential in a large population
(2024) In Scientific Reports 14(1).- Abstract
Medication can affect the gut microbiota composition and function. The aim of this study was to investigate connections between use of common non-antibiotic medicines and the gut microbiota composition and function in a large Swedish cohort (N = 2223). Use of 67 medications and polypharmacy (≥ 5 medications), based on self-reported and prescription registry data, were associated with the relative abundance of 881 gut metagenomic species (> 5% prevalence) and 103 gut metabolic modules (GMMs). Altogether, 97 associations of 26 medications with 40 species and of four medications with five GMMs were observed (false discovery rate < 5%). Several earlier findings were replicated like the positive associations of proton pump inhibitors... (More)
Medication can affect the gut microbiota composition and function. The aim of this study was to investigate connections between use of common non-antibiotic medicines and the gut microbiota composition and function in a large Swedish cohort (N = 2223). Use of 67 medications and polypharmacy (≥ 5 medications), based on self-reported and prescription registry data, were associated with the relative abundance of 881 gut metagenomic species (> 5% prevalence) and 103 gut metabolic modules (GMMs). Altogether, 97 associations of 26 medications with 40 species and of four medications with five GMMs were observed (false discovery rate < 5%). Several earlier findings were replicated like the positive associations of proton pump inhibitors (PPIs) with numerous oral species, and those of metformin with Escherichia species and with lactate consumption I and arginine degradation II. Several new associations were observed between, among others, use of antidepressants, beta-blockers, nonsteroidal anti-inflammatory drugs and calcium channel blockers, and specific species. Polypharmacy was positively associated with Enterococcus faecalis, Bacteroides uniformis, Rothia mucilaginosa, Escherichia coli and Limosilactobacillus vaginalis, and with 13 GMMs. We confirmed several previous findings and identified numerous new associations between use of medications/polypharmacy and the gut microbiota composition and functional potential. Further studies are needed to confirm the new findings.
(Less)
- author
- organization
-
- Diabetes - Cardiovascular Disease (research group)
- EpiHealth: Epidemiology for Health
- EXODIAB: Excellence of Diabetes Research in Sweden
- Department of Clinical Sciences, Malmö
- Cardiovascular Research - Hypertension (research group)
- MultiPark: Multidisciplinary research focused on Parkinson's disease
- Internal Medicine - Epidemiology (research group)
- Translational Diabetes Research (research group)
- publishing date
- 2024-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Gut metabolic modules, Gut microbiota, Medications, Polypharmacy, Population cohort, Shotgun metagenomics
- in
- Scientific Reports
- volume
- 14
- issue
- 1
- article number
- 23723
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:39390025
- scopus:85206055085
- ISSN
- 2045-2322
- DOI
- 10.1038/s41598-024-71571-4
- language
- English
- LU publication?
- yes
- id
- cd9f76fb-7b39-4f3a-9555-cc2d66e1c5ab
- date added to LUP
- 2024-11-27 15:36:09
- date last changed
- 2025-07-10 10:18:34
@article{cd9f76fb-7b39-4f3a-9555-cc2d66e1c5ab, abstract = {{<p>Medication can affect the gut microbiota composition and function. The aim of this study was to investigate connections between use of common non-antibiotic medicines and the gut microbiota composition and function in a large Swedish cohort (N = 2223). Use of 67 medications and polypharmacy (≥ 5 medications), based on self-reported and prescription registry data, were associated with the relative abundance of 881 gut metagenomic species (> 5% prevalence) and 103 gut metabolic modules (GMMs). Altogether, 97 associations of 26 medications with 40 species and of four medications with five GMMs were observed (false discovery rate < 5%). Several earlier findings were replicated like the positive associations of proton pump inhibitors (PPIs) with numerous oral species, and those of metformin with Escherichia species and with lactate consumption I and arginine degradation II. Several new associations were observed between, among others, use of antidepressants, beta-blockers, nonsteroidal anti-inflammatory drugs and calcium channel blockers, and specific species. Polypharmacy was positively associated with Enterococcus faecalis, Bacteroides uniformis, Rothia mucilaginosa, Escherichia coli and Limosilactobacillus vaginalis, and with 13 GMMs. We confirmed several previous findings and identified numerous new associations between use of medications/polypharmacy and the gut microbiota composition and functional potential. Further studies are needed to confirm the new findings.</p>}}, author = {{Larsson, Anna and Ericson, Ulrika and Jönsson, Daniel and Miari, Mariam and Athanasiadis, Paschalis and Baldanzi, Gabriel and Brunkwall, Louise and Hellstrand, Sophie and Klinge, Björn and Melander, Olle and Nilsson, Peter M. and Fall, Tove and Maziarz, Marlena and Orho-Melander, Marju}}, issn = {{2045-2322}}, keywords = {{Gut metabolic modules; Gut microbiota; Medications; Polypharmacy; Population cohort; Shotgun metagenomics}}, language = {{eng}}, number = {{1}}, publisher = {{Nature Publishing Group}}, series = {{Scientific Reports}}, title = {{New connections of medication use and polypharmacy with the gut microbiota composition and functional potential in a large population}}, url = {{http://dx.doi.org/10.1038/s41598-024-71571-4}}, doi = {{10.1038/s41598-024-71571-4}}, volume = {{14}}, year = {{2024}}, }